Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INCONTROL METRIX 3000 ATRIAL DEFIBRILLATOR CLINICALS

This article was originally published in The Gray Sheet

Executive Summary

INCONTROL METRIX 3000 ATRIAL DEFIBRILLATOR CLINICALS are slated to begin in early 1995, the company says in a filing for an initial public offering. Implanted beneath the collarbone with transvenous leads connecting it to the heart, the Metfix system is designed to detect and correct atrial fibrillation. The device is the first product under development by Redmond, Washington-based InControl.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002580

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel